The Global Nintedanib Esylate Market was valued at USD 145.67 Million in 2023 and is projected to reach USD 312.45 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period (2024–2030). This growth is being driven by the rising prevalence of idiopathic pulmonary fibrosis (IPF), expanded indications for systemic sclerosis-associated interstitial lung disease (SSc-ILD), and the surge in generic formulations following patent expirations, bolstering accessibility across pharmaceutical and healthcare sectors.

As the pharmaceutical industry shifts toward precision treatments for progressive fibrotic lung conditions, attention centers on the pivotal API manufacturers propelling innovation, quality assurance, and global supply. In this blog, we profile the Top 10 Companies in the Global Nintedanib Esylate Industry—a combination of originators, generic powerhouses, and specialized API producers defining the trajectory of antifibrotic drug development.

---

🔟 1. Manus Aktteva Biopharma LLP

Headquarters: Pune, India
Key Offering: Nintedanib Esylate API (98% and 99% purity), Pharmaceutical Intermediates

Manus Aktteva Biopharma LLP stands as a prominent supplier in the Nintedanib Esylate space, focusing on high-quality active pharmaceutical ingredients for generic drug makers worldwide. The company excels in process chemistry optimization, ensuring cost-effective production while maintaining stringent regulatory compliance for markets in North America, Europe, and Asia. Their expertise supports the formulation of oral capsules used in IPF therapy, helping bridge supply gaps amid growing demand for affordable treatments.

Key Initiatives:

• Expansion of cGMP-compliant manufacturing facilities
• Strategic partnerships with generic pharma firms for scale-up
• Focus on impurity profiling and stability studies for API excellence

Download FREE Sample Report: Global Nintedanib Esylate Market – View in Detailed Research Report

---

9️⃣ 2. Lupin Limited

Headquarters: Mumbai, India
Key Offering: Nintedanib Esylate API, Finished Dosage Forms for IPF

Lupin Limited has carved a niche in the respiratory therapeutics segment, leveraging its robust R&D to produce Nintedanib Esylate for generic Ofev equivalents. Operating state-of-the-art facilities audited by USFDA and EMA, the company supplies to over 100 countries, emphasizing bioequivalence and therapeutic efficacy. Their vertical integration from API to formulations accelerates market entry for cost-sensitive regions facing high IPF burdens.

Key Initiatives:

• Investment in respiratory portfolio expansion
• Bioequivalence studies across diverse populations
• Global regulatory filings for multiple indications

---

8️⃣ 3. Hetero Drugs Limited

Headquarters: Hyderabad, India
Key Offering: High-Purity Nintedanib Esylate, Organic Intermediates

Hetero Drugs is a vertically integrated player with deep expertise in complex generics, including Nintedanib Esylate for fibrotic lung diseases. Their large-scale API production capabilities, backed by 25+ ANDA approvals, position them strongly in emerging markets. Hetero prioritizes sustainable synthesis routes, reducing environmental impact while delivering consistent quality to support clinical and commercial needs.

Key Initiatives:

• Green chemistry adoption in API synthesis
• Capacity doubling for orphan drug APIs
• Collaborations with CROs for indication expansion

---

7️⃣ 4. Aurobindo Pharma Limited

Headquarters: Hyderabad, India
Key Offering: Nintedanib Esylate (99% purity), Pharmaceutical Intermediates

Aurobindo Pharma excels in API manufacturing for respiratory disorders, supplying Nintedanib Esylate to major generic players globally. With facilities compliant to international standards and a focus on supply chain resilience, the company navigates market volatilities effectively. Their R&D investments target process improvements, enhancing yield and purity for long-term IPF management solutions.

Key Initiatives:

• USFDA-approved expansions for high-potency APIs
• Supply agreements with key markets in Europe and APAC
• Advanced analytical method development

Download FREE Sample Report: Global Nintedanib Esylate Market – View in Detailed Research Report

---

6️⃣ 5. Dr. Reddy’s Laboratories

Headquarters: Hyderabad, India
Key Offering: Nintedanib Esylate API, Custom Synthesis Services

Dr. Reddy’s Laboratories brings innovation to the Nintedanib Esylate market through its global generics leadership and strong US presence. The company’s integrated manufacturing ensures reliable supply for IPF treatments, supported by comprehensive stability data and regulatory dossiers. They actively pursue new therapeutic areas, positioning Nintedanib for broader fibrotic applications.

Key Initiatives:

• Pipeline development for complex generics
• Strategic acquisitions enhancing API capabilities
• Patient-centric access programs in low-income regions

---

5️⃣ 6. Cipla Limited

Headquarters: Mumbai, India
Key Offering: Nintedanib Esylate for Respiratory Therapeutics

Cipla is renowned for affordable healthcare solutions, extending to Nintedanib Esylate production for IPF patients in developing economies. Their end-to-end capabilities from API to inhalers underscore commitment to respiratory health. With WHO prequalification, Cipla ensures quality and affordability, fueling market penetration in underserved areas.

Key Initiatives:

• Affordable medicine initiatives worldwide
• R&D for fixed-dose combinations
• Digital health integrations for patient monitoring

---

4️⃣ 7. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, India
Key Offering: Nintedanib Esylate API (98-99% purity), Finished Products

Sun Pharma, a global generics titan, leads in Nintedanib Esylate with diversified portfolios across chronic therapies. Their cutting-edge facilities and 400+ USFDA approvals enable seamless scaling. Sun focuses on lifecycle management, adapting to evolving regulations and patient needs in fibrotic diseases.

Key Initiatives:

• Specialty generics acceleration
• Investment in biosimilars and novel deliveries
• Global partnerships for market expansion

---

3️⃣ 8. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Generic Nintedanib Esylate, Branded Equivalents

Teva, the world’s largest generic producer, offers Nintedanib Esylate through its extensive respiratory lineup. Serving millions, their supply chain expertise ensures uninterrupted access post-patent. Teva’s innovation in generics drives down costs, making advanced IPF therapy viable for broader populations.

Key Initiatives:

• Portfolio optimization for rare diseases
• Digital supply chain enhancements
• Sustained release formulation research

---

2️⃣ 9. Zhejiang Zetian Fine Chemicals Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Nintedanib Esylate Intermediates, High-Purity API

Zhejiang Zetian Fine Chemicals specializes in fine chemicals for pharma, excelling in Nintedanib Esylate synthesis. As a key Asian supplier, they support global generics with scalable production and competitive pricing. Their tech upgrades focus on efficiency and compliance for international exports.

Key Initiatives:

• Process innovation for cost reduction
• Export compliance certifications
• Expansion into advanced intermediates

---

1️⃣ 10. Boehringer Ingelheim

Headquarters: Ingelheim am Rhein, Germany
Key Offering: OFEV (Nintedanib Esylate), Originator API and Formulations

Boehringer Ingelheim pioneered Nintedanib Esylate as OFEV, the first approved therapy for IPF and SSc-ILD. Their ongoing clinical trials explore new indications like other ILDs, solidifying leadership. With family-owned stability, they invest heavily in R&D, ensuring therapeutic advancements and global availability.

Key Initiatives:

• Phase III trials for expanded indications
• Global access programs for rare diseases
• Precision medicine integrations with biomarkers

Read Full Report: Global Nintedanib Esylate Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Nintedanib Esylate Is Precision and Accessible

The Nintedanib Esylate market is experiencing transformative changes. While originator products maintain premium positioning, generics are rapidly capturing share, alongside investments in novel formulations and combination therapies.

📈 Key Trends Shaping the Market:

• Generic launches accelerating in US, EU, and Asia post-2024 patents
• Regulatory approvals for additional interstitial lung diseases
• Digital tools for patient adherence and real-world evidence
• Pharma alliances for combination antifibrotics

Read Full Report: Global Nintedanib Esylate Market – View in Detailed Research Report

The companies profiled are not only supplying critical APIs—they’re pioneering the next era of fibrotic disease management.

Download FREE Sample Report: Global Nintedanib Esylate Market – View in Detailed Research Report